Prospective Evaluation of Circulating Tumor DNA in Metastatic Hormone-Sensitive Prostate Cancer.
In this diverse cohort, a positive ctDNA TF at baseline was associated with worse outcomes in mHSPC and may potentially complement current further risk stratification tools.